Biomarkers for Tyrosine Kinase Inhibitors in Renal Cell Cancer

Overview

Journal Transl Androl Urol

Date 2016 Jan 28

PMID 26816714

Authors

Nicholas Coupe

Michelle Harrison

Wei Chua

Paul de Souza

Affiliations

Soon will be listed here.

References

Houk B, Bello C, Poland B, Rosen L, Demetri G, Motzer R . Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2009; 66(2):357-71. DOI: 10.1007/s00280-009-1170-y. View

Tomita Y, Uemura H, Fujimoto H, Kanayama H, Shinohara N, Nakazawa H . Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer. 2011; 47(17):2592-602. DOI: 10.1016/j.ejca.2011.07.014. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Ward J, Stadler W . Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010; 16(24):5923-7. DOI: 10.1158/1078-0432.CCR-10-0728. View

Blankenberg F, Levashova Z, Sarkar S, Pizzonia J, Backer M, Backer J . Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol. 2010; 3(1):56-64. PMC: 2822454. DOI: 10.1593/tlo.09271. View

Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M . Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007; 5(6):379-85. DOI: 10.3816/CGC.2007.n.020. View

Brugarolas J . Renal-cell carcinoma--molecular pathways and therapies. N Engl J Med. 2007; 356(2):185-7. DOI: 10.1056/NEJMe068263. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

10.

Pena C, Lathia C, Shan M, Escudier B, Bukowski R . Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010; 16(19):4853-63. DOI: 10.1158/1078-0432.CCR-09-3343. View

11.

Kontovinis L, T Papazisis K, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris A . Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009; 9:82. PMC: 2662874. DOI: 10.1186/1471-2407-9-82. View

12.

Perez-Gracia J, Prior C, Guillen-Grima F, Segura V, Gonzalez A, Panizo A . Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer. 2009; 101(11):1876-83. PMC: 2788252. DOI: 10.1038/sj.bjc.6605409. View

13.

Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I . Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010; 77(9):809-15. DOI: 10.1038/ki.2009.552. View

14.

Motzer R, Bacik J, Schwartz L, Reuter V, Russo P, Marion S . Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22(3):454-63. DOI: 10.1200/JCO.2004.06.132. View

15.

Cohen E, Rosen L, Vokes E, Kies M, Forastiere A, Worden F . Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008; 26(29):4708-13. PMC: 4859206. DOI: 10.1200/JCO.2007.15.9566. View

16.

Atkins M . Management of advanced renal cancer. Kidney Int. 2005; 67(5):2069-82. DOI: 10.1111/j.1523-1755.2005.00309.x. View

17.

DePrimo S, Bello C, Smeraglia J, Baum C, Spinella D, Rini B . Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5:32. PMC: 1939830. DOI: 10.1186/1479-5876-5-32. View

18.

Lopez C, Esteban E, Astudillo A, Pardo P, Berros J, Izquierdo M . Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs. 2012; 30(6):2443-9. DOI: 10.1007/s10637-012-9836-4. View

19.

Kim J, Vaziri S, Rini B, Elson P, Garcia J, Wirka R . Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2011; 118(7):1946-54. PMC: 4124607. DOI: 10.1002/cncr.26491. View

20.

van der Veldt A, Eechoute K, Gelderblom H, Gietema J, Guchelaar H, van Erp N . Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2010; 17(3):620-9. DOI: 10.1158/1078-0432.CCR-10-1828. View